NCT03473639: A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

NCT03473639
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: MBC patients will not be eligible for expansion phase
Exclusions: Known brain metastases unless adequately treated- see trial for details
https://ClinicalTrials.gov/show/NCT03473639

Comments are closed.

Up ↑